|
|
|
Volumn 61, Issue 2, 2006, Pages 295-384
|
|
The Food and Drug Administration's use of postmarketing (phase IV) study requirements: Exception to the rule?
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANASTROZOLE;
ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;
ANTIINFECTIVE AGENT;
ANTIINFLAMMATORY AGENT;
ANTINEOPLASTIC AGENT;
ANTIPARKINSON AGENT;
ANTIPSORIASIS AGENT;
AZARIBINE;
CONTRACEPTIVE AGENT;
CROMOGLYCATE DISODIUM;
CYCLOOXYGENASE 2 INHIBITOR;
DANTROLENE;
DEXFENFLURAMINE;
DIDANOSINE;
ENFLURANE;
INHALATION ANESTHETIC AGENT;
LEVODOPA;
MEDROXYPROGESTERONE ACETATE;
METHADONE;
MUSCLE RELAXANT AGENT;
PREGABALIN;
ROFECOXIB;
TRIAZURE;
VALDECOXIB;
ACQUIRED IMMUNE DEFICIENCY SYNDROME;
ASTHMA;
BLOOD CLOTTING DISORDER;
BREAST CANCER;
CARDIOVASCULAR DISEASE;
DIABETIC NEUROPATHY;
DRUG APPROVAL;
DRUG EFFICACY;
DRUG INDUSTRY;
DRUG SAFETY;
DRUG SURVEILLANCE PROGRAM;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
PARKINSON DISEASE;
PERIPHERAL NEUROPATHY;
POSTMARKETING SURVEILLANCE;
POSTMENOPAUSE;
PSORIASIS;
PULMONARY HYPERTENSION;
REVIEW;
RISK BENEFIT ANALYSIS;
RISK MANAGEMENT;
WEIGHT REDUCTION;
ANTI-HIV AGENTS;
CLINICAL TRIALS, PHASE IV;
DEXFENFLURAMINE;
DRUG APPROVAL;
HISTORY, 20TH CENTURY;
LACTONES;
PRODUCT SURVEILLANCE, POSTMARKETING;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 33745623987
PISSN: 1064590X
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (17)
|
|
References (0)
|